Shared Decision Making on Radiation Dose for Lung Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-12

Study Completion Date

2031-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on the dose of stereotactic body radiation therapy (SBRT) for lung tumors located less than 1 cm from the thoracic wall.

Hypothesis: The use of a PtDA will increase the extent of Shared Decision Making (SDM) during the consultation and result in patients being more directly involved in the planning of their treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient Experience Data in Radiation Oncology

NCT05224297

Radiotherapy Side Effect PROMs

RECRUITING

Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans

NCT00572923

Small Cell Lung Cancer

COMPLETED

PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study

NCT03632603

Lung Cancer

RECRUITING PHASE3

Coagulation System In STereotactic Radiotherapy Of NSCLC

NCT03893461

Thromboembolism Lung Cancer NSCLC +1 more

UNKNOWN

Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer

NCT06329648

NSCLC

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When a lung tumor is located close to the thoracic wall, there is an increased risk of developing chest wall pain or rib fracture following SBRT of the tumor. A meta-analysis has shown the pooled risk of chest wall pain to be 11% and that of rib fracture to be 6.3% with significant differences between individual studies. These side effects may occur several years after the treatment.

SDM is a collaborative process allowing patients and healthcare professionals to make decisions together taking into account the best scientific evidence as well as patients' values, preferences, life situation, and knowledge about disease process and prognosis.

PtDAs are tools designed to assist caregivers in the process of informing patients about relevant treatment options. PtDAs contain factual and balanced information about the options and the pertaining pros, cons, and probabilities. The tools are relevant when the decision is preference-sensitive, that is, the right treatment cannot be decided based on professional knowledge alone. The use of PtDAs has shown to provide a number of positive effects on the patients, including increased knowledge of options, better understanding of risks, and clarity as to what matters most in their life situation. Other effects are decreased decisional conflict and a higher degree of involvement in decision making.

This is a randomized trial enrolling eligible patients during a period of 16 months. SDM will be used in the planning of SBRT to patients with peripheral non-small cell lung tumors or lung metastases and offer them the choice between high (66 Gy in 3 fractions) and low (45 Gy in 3 fractions) radiation dose.

A total of 40 patients will be included in the study, i.e. 20 patients in each arm.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Decision Making, Shared Stereotactic Body Radiation Therapy Lung Cancer, Non-small Cell Radiation Toxicity Lung Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After inclusion in the study, the patients are randomized into Arm A and B as follows:

Arm A: Consultation as usual. Patients are informed about treatment and the two dose options according to current standards and routines.

Arm B: Consultation using the PtDA. Patients are informed about treatment and dose options using the PtDA to make the pros and cons clearer to the patients.

The doctors and nurses in the Radiotherapy Department will be educated in the use of the PtDA before initiation of the study.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A - control

The patients are offered high or lower dose according to usual practice

Group Type NO_INTERVENTION

No interventions assigned to this group

B - Intervention

The Patient Decision Aid is used during the consultation to aid in the decision on high or lower dose.

Group Type EXPERIMENTAL

A Patient Decision Aid

Intervention Type BEHAVIORAL

The Patient Decision Aid informs about the pros and cons of each option

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A Patient Decision Aid

The Patient Decision Aid informs about the pros and cons of each option

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located ≤ 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference.
* Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66/45 Gy in 3 fractions) following national guidelines (2).
* Can read and understand Danish.
* Written and orally informed consent.
* Performance status 0-2
* Life expectancy \> 6 months assessed by the physician during the consultation.

Exclusion Criteria

* Previous radiation therapy in the thoracic region (lung, breast or mediastinum), if it is not possible to produce a new radiation plan of 66 or 45 Gy in 3 fractions that considers previous radiation therapy and still complies with all constraints, including dose to the thoracic wall. Previous surgery in the thorax is allowed.
* Mental or social conditions preventing full understanding of the information or the planned treatment and follow-up.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No